董事
|
| |
年龄
|
| |
第一年
变成了 董事 |
| |
当前
公共 板 |
|
卡伦·L·肖斯(董事会主席) | | |
69
|
| |
2001
|
| |
1
|
|
安东尼·S·马鲁奇(首席执行官) | | |
61
|
| |
2008
|
| |
2
|
|
基思·L·布朗利 | | |
70
|
| |
2017
|
| |
1
|
|
谢丽尔·L·科恩 | | |
57
|
| |
2022
|
| |
2
|
|
赫伯特·J·康拉德 | | |
90
|
| |
2008
|
| |
2
|
|
丽塔·I·贾恩医学博士 | | |
61
|
| |
2023
|
| |
3
|
|
詹姆斯·J·马里诺 | | |
73
|
| |
2017
|
| |
2
|
|
加里·A·尼尔医学博士。 | | |
69
|
| |
2022
|
| |
2
|
|
小哈里·H·彭纳 | | |
77
|
| |
1997
|
| |
1
|
|
属性、经验和技能
|
| |
凯伦·L·
鞋 |
| |
Anthony S.
马鲁奇 |
| |
基思·L·
布朗利 |
| |
谢丽尔·L·
科恩 |
| |
赫伯特·J·
康拉德 |
| |
丽塔·I
[br]Jain医学博士 |
| |
James J.
马里诺 |
| |
Garry A.
尼尔,医学博士。 |
| |
哈里·H
小彭纳 |
| |||||||||||||||||||||||||||
行业经验
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
高管/领导力经验
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
科学研究/药物开发
体验 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
*
|
| | | | | | | | | |
|
*
|
| | | | | | | |
业务战略/运营经验
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
金融经验
|
| | | | | | | | | | * | | | | | | * | | | | | | * | | | | | | | | | | | | | | | | | | * | | | | | | | | | | | | * | | |
商业体验
|
| | | | | | | | | | | | | | | | | | | | | | * | | | | | | * | | | | | | | | | | | | | | | | | | | | | | | | | | |
并购经验
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
上市公司董事会经验
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
人口统计 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
种族/民族 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
亚洲人
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | * | | | | | | | | | | | | | | | | | | | | |
白色
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | | | | | | | * | | | | | | * | | | | | | * | | |
性别 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
女性
|
| | | | * | | | | | | | | | | | | | | | | | | * | | | | | | | | | | | | * | | | | | | | | | | | | | | | | | | | | |
男性
|
| | | | | | | | | | * | | | | | | * | | | | | | | | | | | | * | | | | | | | | | | | | * | | | | | | * | | | | | | * | | |
董事会规模:董事总数
|
| |
9
|
| |||||||||||||||||||||
性别:
|
| |
男性
|
| |
女性
|
| |
非二进制
|
| |
性别
未披露 |
| ||||||||||||
董事
|
| | | | 6 | | | | | | 3 | | | | | | — | | | | | | — | | |
人口统计背景: | | | | | | | | | | | | | | | | | | | | | | | | | |
非裔美国人或黑人
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
阿拉斯加原住民或原住民
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
亚洲人
|
| | | | — | | | | | | 1 | | | | | | — | | | | | | — | | |
西班牙裔或拉丁裔
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
夏威夷原住民或太平洋岛民
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
白色
|
| | | | 6 | | | | | | 2 | | | | | | — | | | | | | — | | |
两个或两个以上种族或民族
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LGBTQ+
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
未披露
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
个人姓名
|
| |
年龄
|
| |
职位和办公室
|
|
安东尼·S·马鲁奇 | | |
61
|
| | 董事首席执行官总裁 | |
Tibor Keler博士 | | |
64
|
| | 总裁常务副主任兼首席科学官 | |
萨拉·卡瓦诺 | | |
48
|
| | 高级副总裁,企业事务与行政 | |
伊丽莎白·克劳利 | | |
51
|
| | 高级副总裁和首席产品开发官 | |
Margo Heath-Chiozzi医学博士 | | |
66
|
| | 高级副总裁,监管事务 | |
弗雷迪·希门尼斯 | | |
54
|
| | 高级副总裁与总法律顾问 | |
萨姆·马丁 | | |
52
|
| | 首席财务官兼秘书高级副总裁 | |
罗纳德·佩平,博士。 | | |
67
|
| | 高级副总裁与首席商务官 | |
理查德·赖特博士。 | | |
59
|
| | 高级副总裁与首席商务官 | |
戴安·C·杨医学博士。 | | |
67
|
| | 首席医疗官高级副总裁 | |
个人姓名
|
| |
职位和办公室
|
|
安东尼·S·马鲁奇 | | | 董事首席执行官总裁 | |
Tibor Keler博士 | | | 总裁常务副主任兼首席科学官 | |
Margo Heath-Chiozzi医学博士 | | | 高级副总裁,监管事务 | |
萨姆·马丁 | | | 首席财务官兼秘书高级副总裁 | |
戴安·C·杨医学博士。 | | | 首席医疗官高级副总裁 | |
| 阿拉科斯 | | | ITeos治疗公司 | |
| Atara生物治疗学 | | | Kiniksa制药公司 | |
| C4治疗学 | | | 形态 | |
| 细胞动力学 | | | 主人公治疗公司 | |
| 德纳利治疗公司 | | | Sangamo治疗公司 | |
| 埃南塔制药公司 | | | 塞雷斯治疗公司 | |
| 埃拉斯卡 | | | SpringWorks治疗公司 | |
| 免疫生物 | | | Syndax制药公司 | |
| Inovio制药公司 | | | VIR生物技术 | |
| 爱万斯生物治疗学 | | | Zentaris制药公司 | |
| | |
年薪
|
| | | | | | | | | | | | | |||||||||
名字
|
| |
截至2013年12月31日
2022 |
| |
截至2013年12月31日
2021 |
| |
增加
$ |
| |
增加
% |
| ||||||||||||
安东尼·S·马鲁奇
|
| | | $ | 708,144 | | | | | $ | 680,908 | | | | | $ | 27,236 | | | | | | 4.0% | | |
Tibor Keler博士
|
| | | $ | 500,573 | | | | | $ | 483,645 | | | | | $ | 16,928 | | | | | | 3.5% | | |
Margo Heath-Chiozzi医学博士
|
| | | $ | 432,278 | | | | | $ | 417,660 | | | | | $ | 14,618 | | | | | | 3.5% | | |
萨姆·马丁
|
| | | $ | 439,654 | | | | | $ | 412,820 | | | | | $ | 26,834 | | | | | | 6.5% | | |
戴安·C·杨医学博士。
|
| | | $ | 453,476 | | | | | $ | 438,141 | | | | | $ | 15,335 | | | | | | 3.5% | | |
2022年企业目标
|
| |
相对
重量 |
| |
2022
成就 |
| ||||||
管道开发:
|
| | | | 75 | | | | | | 100% | | |
CDX-0159 | | | | | | | | | | | | | |
•
在医学会议上报告慢性荨麻疹(CSU和Cindu)1b期临床计划的结果
|
| | | | | | | | | | | | |
•
完成第1b阶段PN学习的注册
|
| | | | | | | | | | | | |
•
提供第一阶段高压SC试验的最终结果
|
| | | | | | | | | | | | |
•
在CSU和Cindu启动第2阶段试验
|
| | | | | | | | | | | | |
•
选择并启动第四适应症的临床试验
|
| | | | | | | | | | | | |
•
提供中期和最终的慢性毒理学结果
|
| | | | | | | | | | | | |
•
确定并实施儿科发展战略
|
| | | | | | | | | | | | |
•
管理CMO活动以实现成功的技术转让和流程优化
|
| | | | | | | | | | | | |
•
生产额外的CDX-0159,以确保提供适当数量的CDX-0159支持临床计划
|
| | | | | | | | | | | | |
•
为CSU、Cindu和PN开发患者行程模型
|
| | | | | | | | | | | | |
免疫炎症组合:临床前组合 | | | | | | | | | | | | | |
•
抗SCF方案的完整表征和POC研究
|
| | | | | | | | | | | | |
•
适当地启动制造活动
|
| | | | | | | | | | | | |
•
更多靶标/抗体的进展活动和评价
|
| | | | | | | | | | | | |
CDX-1140 | | | | | | | | | | | | | |
•
与pbro相结合交付结果,以支持进行/不进行决策并定义未来发展战略
|
| | | | | | | | | | | | |
•
履行桥梁拨款承诺,包括监督CDX-1140的外部临床开发和制造(如果有保证)
|
| | | | | | | | | | | | |
2022年企业目标
|
| |
相对
重量 |
| |
2022
成就 |
| ||||||
CDX-527 | | | | | | | | | | | | | |
•
在CDX-527第一阶段试验中提供肿瘤定向扩展队列的结果,以支持进行/不进行决策并定义未来发展战略
|
| | | | | | | | | | | | |
CDX-585 | | | | | | | | | | | | | |
•
执行IND支持活动,包括CMC和毒理学,以支持IND提交
|
| | | | | | | | | | | | |
肿瘤学投资组合:临床前投资组合 | | | | | | | | | | | | | |
•
通过临床前测试支持潜在的临床组合
|
| | | | | | | | | | | | |
•
评估感兴趣的优先目标
|
| | | | | | | | | | | | |
商业和金融运营:
|
| | | | 25 | | | | | | 100% | | |
•
根据当前的现金消耗假设,到2025年保持现金跑道
|
| | | | | | | | | | | | |
•
保持85%以上的机构所有权,重点发展我们与长期驱动的、专注于医疗保健的基金的关系
|
| | | | | | | | | | | | |
•
实施计划以提高对肥大细胞引起的疾病和细胞科学的认识,以支持企业品牌和临床试验计划
|
| | | | | | | | | | | | |
•
执行DE&I计划,重点是在Celldex广泛促进包容性和多样性,并探索确保我们的行业拥有强大和多样化的人才渠道的方法
|
| | | | | | | | | | | | |
•
锐化战略招聘计划,重点招聘与Celldex文化相融合的顶级人才
|
| | | | | | | | | | | | |
•
转向适用于内部/外部许可、协作或并购交易的条款说明书
|
| | | | | | | | | | | | |
总计:
|
| | | | 100 | | | | | | 100% | | |
|
名字
|
| |
目标百分比
|
| |
最终支付百分比
|
| |
最终
支出 $ |
| |||||||||
安东尼·S·马鲁奇
|
| | | | 60% | | | | | | 60.0% | | | | | $ | 424,886 | | |
Tibor Keler博士
|
| | | | 45% | | | | | | 47.7% | | | | | $ | 238,773 | | |
Margo Heath-Chiozzi,医学博士
|
| | | | 40% | | | | | | 42.4% | | | | | $ | 183,286 | | |
萨姆·马丁
|
| | | | 40% | | | | | | 41.6% | | | | | $ | 182,896 | | |
戴安·C·杨医学博士。
|
| | | | 40% | | | | | | 42.4% | | | | | $ | 192,274 | | |
名字
|
| |
数量:
选项 |
| |
行使价
($/Sh)(1) |
| |
授予日期
公允价值 选项奖 ($)(2) |
| |||||||||
安东尼·S·马鲁奇
|
| | | | 250,000 | | | | | | 22.48 | | | | | | 4,262,250 | | |
Tibor Keler博士
|
| | | | 91,000 | | | | | | 22.48 | | | | | | 1,551,459 | | |
Margo Heath-Chiozzi,医学博士
|
| | | | 77,000 | | | | | | 22.48 | | | | | | 1,312,773 | | |
萨姆·马丁
|
| | | | 85,000 | | | | | | 22.48 | | | | | | 1,449,165 | | |
戴安·杨医学博士
|
| | | | 76,000 | | | | | | 22.48 | | | | | | 1,295,724 | | |
水平
|
| |
最低要求
股权级别 |
|
首席执行官
|
| |
年基本工资的3倍
|
|
其他行政主任
|
| |
年基本工资的1倍
|
|
名称和主要职位
|
| |
年份
|
| |
工资
($) |
| |
奖金
($)(1) |
| |
库存
奖项 ($) |
| |
选项
奖项 ($)(2) |
| |
非股权
奖励 计划 薪酬 ($) |
| |
在
中更改
养老金 值和 不合格 延期 薪酬 收入 ($) |
| |
所有其他
薪酬 ($)(3) |
| |
合计
($) |
| |||||||||||||||||||||||||||
安东尼·S·马鲁奇
总裁和科长 执行主任 |
| | | | 2022 | | | | | | 693,479 | | | | | | 424,886 | | | | | | — | | | | | | 4,262,250 | | | | | | — | | | | | | — | | | | | | 20,668 | | | | | | 5,401,283 | | |
| | | 2021 | | | | | | 668,509 | | | | | | 490,254 | | | | | | — | | | | | | 4,868,797 | | | | | | — | | | | | | — | | | | | | 18,334 | | | | | | 6,045,894 | | | ||
| | | 2020 | | | | | | 644,257 | | | | | | 395,000 | | | | | | — | | | | | | 1,950,788 | | | | | | — | | | | | | — | | | | | | 16,623 | | | | | | 3,006,668 | | | ||
Tibor Keler博士
执行副总裁 总裁和首席科学官 |
| | | | 2022 | | | | | | 491,458 | | | | | | 238,773 | | | | | | — | | | | | | 1,551,459 | | | | | | — | | | | | | — | | | | | | 8,796 | | | | | | 2,290,486 | | |
| | | 2021 | | | | | | 475,030 | | | | | | 265,000 | | | | | | — | | | | | | 1,977,949 | | | | | | — | | | | | | — | | | | | | 8,483 | | | | | | 2,726,462 | | | ||
| | | 2020 | | | | | | 457,405 | | | | | | 190,000 | | | | | | — | | | | | | 859,939 | | | | | | — | | | | | | — | | | | | | 7,508 | | | | | | 1,514,852 | | | ||
Margo Heath-Chiozzi医学博士
高级副总裁,监管事务 |
| | | | 2022 | | | | | | 424,406 | | | | | | 183,286 | | | | | | — | | | | | | 1,312,773 | | | | | | — | | | | | | — | | | | | | 6,433 | | | | | | 1,926,898 | | |
| | | 2021 | | | | | | 409,274 | | | | | | 210,000 | | | | | | — | | | | | | 1,358,481 | | | | | | — | | | | | | — | | | | | | 6,232 | | | | | | 1,983,987 | | | ||
| | | 2020 | | | | | | 393,558 | | | | | | 149,000 | | | | | | — | | | | | | 668,842 | | | | | | — | | | | | | — | | | | | | 6,203 | | | | | | 1,217,603 | | | ||
萨姆·马丁
高级副总裁 和首席财务官 |
| | | | 2022 | | | | | | 425,205 | | | | | | 182,896 | | | | | | — | | | | | | 1,449,165 | | | | | | — | | | | | | — | | | | | | 9,155 | | | | | | 2,066,421 | | |
| | | 2021 | | | | | | 405,303 | | | | | | 205,000 | | | | | | — | | | | | | 1,847,535 | | | | | | — | | | | | | — | | | | | | 9,044 | | | | | | 2,466,882 | | | ||
| | | 2020 | | | | | | 391,397 | | | | | | 142,000 | | | | | | — | | | | | | 840,829 | | | | | | — | | | | | | — | | | | | | 8,671 | | | | | | 1,382,897 | | | ||
戴安·C·杨医学博士。
高级副总裁, 首席医疗官 |
| | | | 2022 | | | | | | 445,219 | | | | | | 192,274 | | | | | | — | | | | | | 1,295,724 | | | | | | — | | | | | | — | | | | | | 6,004 | | | | | | 1,939,221 | | |
| | | 2021 | | | | | | 430,163 | | | | | | 200,000 | | | | | | — | | | | | | 1,564,970 | | | | | | — | | | | | | — | | | | | | 5,834 | | | | | | 2,200,967 | | | ||
| | | 2020 | | | | | | 415,128 | | | | | | 140,000 | | | | | | — | | | | | | 573,293 | | | | | | — | | | | | | — | | | | | | 5,584 | | | | | | 1,134,005 | | |
名字
|
| |
赠款
日期 |
| |
预计未来
项下的支出 股权激励计划和奖励 |
| |
所有其他
库存 奖项: 数量: 股票数量: 库存或单位 (#) |
| |
所有其他
选项 奖项: 数量: 证券 基础选项 (#) |
| |
锻炼或
基本价格为 选项奖 ($/Sh)(1) |
| |
授予日期
公允价值 库存和 选项奖 ($)(2) |
| ||||||||||||||||||
|
阈值
(#) |
| |
目标
(#) |
| |
最大值
(#) |
| |||||||||||||||||||||||||||||
安东尼·S·马鲁奇
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 250,000 | | | | | | 22.48 | | | | | | 4,262,250 | | |
Tibor Keler博士
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 91,000 | | | | | | 22.48 | | | | | | 1,551,459 | | |
Margo Heath-Chiozzi,医学博士
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 77,000 | | | | | | 22.48 | | | | | | 1,312,773 | | |
萨姆·马丁
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 85,000 | | | | | | 22.48 | | | | | | 1,449,165 | | |
戴安·杨医学博士
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 76,000 | | | | | | 22.48 | | | | | | 1,295,724 | | |
| | |
期权大奖
|
| |
股票大奖
|
| |||||||||||||||||||||||||||||||||
名字
|
| |
数量:
证券 底层 未练习 选项(#) 可行使 |
| |
数量:
证券 底层 未练习 选项(#) 不可执行 |
| |
股权
奖励 计划 奖项: 数量: 证券 底层 未练习 未赚到的 选项 (#) |
| |
选项
练习 价格(美元) |
| |
选项
过期 日期 |
| |
数量:
个股票或 单位: 库存 那个 没有 已授予(#) |
| |
市场
值为 个股票或 单位: 库存 那个 没有 已授予($) |
| |
股权
奖励 计划 奖项: 数量: 未赚到的 个共享, 个单位或 其他 权利 那个 没有 已授予(#) |
| |
股权
奖励 计划 奖项: 市场或 支出 值为 未赚到的 个共享, 个单位或 其他 权利 那个 没有 已授予(#) |
| ||||||||||||
安东尼·S·马鲁奇(1)
|
| | | | — | | | | | | 250,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇(1)
|
| | | | 84,000 | | | | | | 140,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇(1)
|
| | | | 153,125 | | | | | | 91,875 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇(1)
|
| | | | 12,500 | | | | | | 12,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇
|
| | | | 26,665 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇
|
| | | | 31,665 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇
|
| | | | 31,665 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇
|
| | | | 18,666 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇
|
| | | | 18,666 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
安东尼·S·马鲁奇
|
| | | | 18,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Tibor Keler博士(1)
|
| | | | — | | | | | | 91,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
Tibor Keler博士(1)
|
| | | | 34,125 | | | | | | 56,875 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
| | |
期权大奖
|
| |
股票大奖
|
| |||||||||||||||||||||||||||||||||
名字
|
| |
数量:
证券 底层 未练习 选项(#) 可行使 |
| |
数量:
证券 底层 未练习 选项(#) 不可执行 |
| |
股权
奖励 计划 奖项: 数量: 证券 底层 未练习 未赚到的 选项 (#) |
| |
选项
练习 价格(美元) |
| |
选项
过期 日期 |
| |
数量:
个股票或 单位: 库存 那个 没有 已授予(#) |
| |
市场
值为 个股票或 单位: 库存 那个 没有 已授予($) |
| |
股权
奖励 计划 奖项: 数量: 未赚到的 个共享, 个单位或 其他 权利 那个 没有 已授予(#) |
| |
股权
奖励 计划 奖项: 市场或 支出 值为 未赚到的 个共享, 个单位或 其他 权利 那个 没有 已授予(#) |
| ||||||||||||
Tibor Keler博士(1)
|
| | | | 67,500 | | | | | | 40,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Tibor Keler博士(1)
|
| | | | 35,640 | | | | | | 7,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 25,999 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 10,799 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 10,799 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 7,766 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 7,766 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 7,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,医学博士(1)
|
| | | | — | | | | | | 77,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,医学博士(1)
|
| | | | 23,437 | | | | | | 39,063 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,医学博士(1)
|
| | | | 52,500 | | | | | | 31,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,医学博士(1)
|
| | | | 36,425 | | | | | | 5,375 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,医学博士
|
| | | | 8,332 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,医学博士
|
| | | | 5,000 | | | | | | — | | | | | | | | | 45.15 | | | | | | 10/3/27 | | | | | | | | | | | | | | |
萨姆·马丁(1)
|
| | | | — | | | | | | 85,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
萨姆·马丁(1)
|
| | | | 31,875 | | | | | | 53,125 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
萨姆·马丁(1)
|
| | | | 66,000 | | | | | | 39,600 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
萨姆·马丁(1)
|
| | | | 5,375 | | | | | | 5,375 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
萨姆·马丁
|
| | | | 3,201 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
萨姆·马丁
|
| | | | 4,332 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
萨姆·马丁
|
| | | | 1,399 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
萨姆·马丁
|
| | | | 1,399 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
萨姆·马丁
|
| | | | 799 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
萨姆·马丁
|
| | | | 500 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
戴安·杨,医学博士(1)
|
| | | | — | | | | | | 76,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
戴安·杨,医学博士(1)
|
| | | | 27,000 | | | | | | 45,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
戴安·杨,医学博士(1)
|
| | | | 21,400 | | | | | | 27,000 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
戴安·杨,医学博士(1)
|
| | | | 3,750 | | | | | | 11,250 | | | | | | | | | 2.71 | | | | | | 7/8/29 | | | | | | | | | | | | | | |
| | |
期权大奖
|
| |
股票大奖
|
| ||||||||||||||||||
名字
|
| |
股份数量
收购日期: 练习 (#) |
| |
实现的价值
练习 ($)(1) |
| |
股份数量
收购日期: 归属 (#) |
| |
实现的价值
关于归属问题 ($) |
| ||||||||||||
安东尼·S·马鲁奇
|
| | | | 120,000 | | | | | | 3,905,158 | | | | | | — | | | | | | — | | |
Tibor Keler博士
|
| | | | 16,860 | | | | | | 575,740 | | | | | | — | | | | | | — | | |
Margo Heath-Chiozzi,医学博士
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
萨姆·马丁
|
| | | | 20,000 | | | | | | 634,899 | | | | | | — | | | | | | — | | |
戴安·杨医学博士
|
| | | | 64,000 | | | | | | 2,042,396 | | | | | | — | | | | | | — | | |
终止合同时的高管福利和付款
|
| |
自愿
辞职 没有用 原因 |
| |
自愿
辞职 永远做好 原因(1) |
| |
终止
由Celldex制作 没有 原因(1) |
| |
终止
由Celldex制作 原因 |
| |
自愿终止
由高管执行 有充分的理由 或由 终止 不带Celldex的 连接中的原因 带有或紧随其后的 控制权变更(2) |
| |||||||||||||||
安东尼·S·马鲁奇 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工资
|
| | | $ | — | | | | | $ | 1,416,288 | | | | | $ | 1,416,288 | | | | | $ | — | | | | | $ | 1,416,288 | | |
奖金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 980,508 | | |
股权奖励加速(3)
|
| | | | — | | | | | | 2,876,471 | | | | | | 2,876,471 | | | | | | — | | | | | | 11,505,881 | | |
延续健康福利
|
| | | | — | | | | | | 40,320 | | | | | | 40,320 | | | | | | — | | | | | | 40,320 | | |
总计
|
| | | $ | — | | | | | $ | 4,333,079 | | | | | $ | 4,333,079 | | | | | $ | — | | | | | $ | 13,942,997 | | |
Tibor Keler博士 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工资
|
| | | $ | — | | | | | $ | 500,573 | | | | | $ | 500,573 | | | | | $ | — | | | | | $ | 1,001,146 | | |
奖金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 397,500 | | |
股权奖励加速(3)
|
| | | | — | | | | | | 1,162,683 | | | | | | 1,162,683 | | | | | | — | | | | | | 4,650,729 | | |
延续健康福利
|
| | | | — | | | | | | 29,790 | | | | | | 29,790 | | | | | | — | | | | | | 29,790 | | |
总计
|
| | | $ | — | | | | | $ | 1,693,046 | | | | | $ | 1,693,046 | | | | | $ | — | | | | | $ | 6,079,165 | | |
Margo Heath-Chiozzi,医学博士 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工资
|
| | | $ | — | | | | | $ | 432,278 | | | | | $ | 432,278 | | | | | $ | — | | | | | $ | 864,556 | | |
奖金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 315,000 | | |
股权奖励加速(3)
|
| | | | — | | | | | | 912,453 | | | | | | 912,453 | | | | | | — | | | | | | 3,649,810 | | |
延续健康福利
|
| | | | — | | | | | | 29,790 | | | | | | 29,790 | | | | | | — | | | | | | 29,790 | | |
总计
|
| | | $ | — | | | | | $ | 1,374,521 | | | | | $ | 1,374,521 | | | | | $ | — | | | | | $ | 4,859,156 | | |
萨姆·马丁 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工资
|
| | | $ | — | | | | | $ | 439,654 | | | | | $ | 439,654 | | | | | $ | — | | | | | $ | 879,308 | | |
奖金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 307,500 | | |
股权奖励加速(3)
|
| | | | — | | | | | | 1,084,119 | | | | | | 1,084,119 | | | | | | — | | | | | | 4,336,476 | | |
延续健康福利
|
| | | | — | | | | | | 40,320 | | | | | | 40,320 | | | | | | — | | | | | | 40,320 | | |
总计
|
| | | $ | — | | | | | $ | 1,564,093 | | | | | $ | 1,564,093 | | | | | $ | — | | | | | $ | 5,563,604 | | |
终止合同时的高管福利和付款
|
| |
自愿
辞职 没有用 原因 |
| |
自愿
辞职 永远做好 原因(1) |
| |
终止
由Celldex制作 没有 原因(1) |
| |
终止
由Celldex制作 原因 |
| |
自愿终止
由高管执行 有充分的理由 或由 终止 不带Celldex的 连接中的原因 带有或紧随其后的 控制权变更(2) |
| |||||||||||||||
戴安·杨医学博士 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工资
|
| | | $ | — | | | | | $ | 453,476 | | | | | $ | 453,476 | | | | | $ | — | | | | | $ | 906,952 | | |
奖金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 300,000 | | |
股权奖励加速(3)
|
| | | | — | | | | | | 954,637 | | | | | | 954,637 | | | | | | — | | | | | | 3,818,545 | | |
延续健康福利
|
| | | | — | | | | | | 13,410 | | | | | | 13,410 | | | | | | — | | | | | | 13,410 | | |
总计
|
| | | $ | — | | | | | $ | 1,421,523 | | | | | $ | 1,421,523 | | | | | $ | — | | | | | $ | 5,038,907 | | |
|
计划和类别
|
| |
(a)
待发行证券数量 行权后签发 未完成的选项和 权利(1) |
| |
(b)
加权平均锻炼 未偿还价格 选项和权利 |
| |
(c)
证券数量 剩余时间为 未来股权项下发行 薪酬计划 (不包括证券 反映在(A)栏中) |
| |||||||||
证券持有人批准的股权补偿计划(2)
|
| | | | 5,085,662(3) | | | | | $ | 29.26 | | | | | | 2,014,200(4) | | |
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | (g) | | | (h) | | | (i) | | ||||||||||||||||||||||||
财政年度结束 12月31日, | | | 摘要 补偿 表合计 聚氧乙烯 | | | 补偿 实际上 支付给PEO(2) | | | 平均摘要 补偿 表合计 非近地轨道近地天体(1) | | | 平均值 补偿 实际支付给 非近地轨道近地天体(2) | | | 初始值 固定$100 以投资为主 关于道达尔 股东 返回 | | | 初始值 固定$100 以投资为主 论同辈群体 总股东数 返回(3) | | | 净亏损(In 数千人) | | | 投资余额 (单位:千)(4) | | ||||||||||||||||||||||||
2022 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | | |||||||
2021 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | | |||||||
2020 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | |
| | | 调整 | | |||||||||||||||||||||||||||||||||
| | | 摘要 补偿 表合计 | | | 少于:授予日期 的公允价值 期权大奖 在此期间授予 本财政年度(a) | | | 地址:年终交易会 卓越的价值 和非既得选择权 授予的奖项 在财政年度内(b) | | | 根据变化进行调整 的公允价值 杰出的和 非既得性期权 获奖时间: 上一财政年度(b) | | | 根据变化进行调整 期权公允价值 获奖时间: 上一财政年度 在此期间归属的 本财政年度(b) | | | 补偿 实际支付 | | ||||||||||||||||||
聚氧乙烯 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2022 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | ( | | | | | $ | | | ||||
2021 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | | |||||
2020 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | | |||||
非近地轨道平均近地天体 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2022 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | ( | | | | | $ | | | ||||
2021 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | | |||||
2020 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | |
名字
|
| |
费用
挣得或 现金支付 ($) |
| |
库存
奖项 ($) |
| |
选项
奖项 ($)(1) |
| |
非股权
奖励计划 薪酬 ($) |
| |
在
中更改
养老金 值和 不合格 延期 薪酬 收入 |
| |
所有其他
薪酬 ($) |
| |
合计
($) |
| |||||||||||||||||||||
凯伦·L·肖斯
|
| | | | 76,979 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 308,845 | | |
基思·L·布朗利
|
| | | | 61,979 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 293,845 | | |
谢丽尔·L·科恩(2)
|
| | | | 39,505 | | | | | | — | | | | | | 463,733 | | | | | | — | | | | | | — | | | | | | — | | | | | | 503,238 | | |
赫伯特·J·康拉德
|
| | | | 53,505 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 285,371 | | |
詹姆斯·J·马里诺
|
| | | | 65,816 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 297,682 | | |
加里·A·尼尔医学博士。(2)
|
| | | | 34,185 | | | | | | — | | | | | | 463,733 | | | | | | — | | | | | | — | | | | | | — | | | | | | 497,918 | | |
小哈里·H·彭纳
|
| | | | 58,679 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 290,545 | | |
实益拥有人姓名或名称及营业地址*
|
| |
金额和性质
受益所有权(1) |
| |
百分比:
普通股(2) |
| ||||||
5%持有者
|
| | | | | | | | | | | | |
FMR有限责任公司
夏日大街245号 马萨诸塞州波士顿,邮编:02210 |
| | |
|
7,064,974(3)
|
| | | |
|
15.0%
|
| |
惠灵顿管理集团有限责任公司
国会街280号 马萨诸塞州波士顿,邮编:02210 |
| | |
|
4,647,912(4)
|
| | | |
|
9.8%
|
| |
贝莱德股份有限公司
东55号52发送街道 纽约,NY 10055 |
| | |
|
3,224,716(5)
|
| | | |
|
6.8%
|
| |
RTW投资公司,LP
40 10这是大道7楼 7这是Floor New York,NY 10014 |
| | |
|
3,084,215(6)
|
| | | |
|
6.5%
|
| |
先锋集团
先锋大道100号 宾夕法尼亚州马尔文,邮编19355 |
| | |
|
2,513,564(7)
|
| | | |
|
5.3%
|
| |
董事被提名和被任命的高管
|
| | | | | | | | | | | | |
基思·L·布朗利
|
| | |
|
34,165(8)
|
| | | |
|
**
|
| |
谢丽尔·L·科恩
|
| | |
|
—
|
| | | |
|
**
|
| |
赫伯特·J·康拉德
|
| | |
|
37,481(9)
|
| | | |
|
**
|
| |
Margo Heath-Chiozzi医学博士
|
| | |
|
149,331(10)
|
| | | |
|
**
|
| |
丽塔·I·贾恩医学博士
|
| | |
|
—
|
| | | |
|
**
|
| |
Tibor Keler博士
|
| | |
|
231,604(11)
|
| | | |
|
**
|
| |
詹姆斯·J·马里诺
|
| | |
|
46,203(12)
|
| | | |
|
**
|
| |
萨姆·马丁
|
| | |
|
153,857(13)
|
| | | |
|
**
|
| |
安东尼·S·马鲁奇
|
| | |
|
459,237(14)
|
| | | |
|
1.0%
|
| |
加里·A·尼尔医学博士。
|
| | |
|
—
|
| | | |
|
**
|
| |
实益拥有人姓名或名称及营业地址*
|
| |
金额和性质
受益所有权(1) |
| |
百分比:
普通股(2) |
| ||||||
小哈里·H·彭纳
|
| | |
|
37,708(15)
|
| | | |
|
**
|
| |
凯伦·L·肖斯
|
| | |
|
37,703(16)
|
| | | |
|
**
|
| |
戴安·C·杨医学博士。
|
| | |
|
115,765(17)
|
| | | |
|
**
|
| |
所有董事被提名人和高管(18人)
|
| | |
|
1,793,754(18)
|
| | | |
|
3.7%
|
| |
费用类别
|
| |
2022
|
| |
2021
|
| ||||||
| | |
(单位:千)
|
| |||||||||
审计费
|
| | | $ | 737 | | | | | $ | 653 | | |
审计相关费用
|
| | | | — | | | | | | — | | |
税费
|
| | | | — | | | | | | — | | |
所有其他费用
|
| | | | 3 | | | | | | 3 | | |
总费用
|
| | | $ | 740 | | | | | $ | 658 | | |